FDA panel to review Grail's blood-based cancer test

The FDA advisory committee will review Grail's premarket approval application for its multi-cancer early detection blood test, Galleri, following trials showing moderate cancer detection rates and low false positives. This review represents the first regulatory assessment of a multi-cancer early detection test in the US.

This Wire brief sits within Fusion42's coverage of Medtech.